Published in Am J Hematol on April 04, 2012
PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding | NCT02557672
Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care (2013) 3.65
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults. Blood Transfus (2015) 1.46
Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol (2012) 1.23
Should direct thrombin inhibitors replace warfarin for prophylaxis of thromboembolism in canadians with atrial fibrillation? Can J Hosp Pharm (2012) 1.07
The perioperative management of treatment with anticoagulants and platelet aggregation inhibitors. Dtsch Arztebl Int (2013) 1.07
Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS One (2013) 1.00
Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol (2013) 0.98
Treatment options for venous thromboembolism: lessons learnt from clinical trials. Thromb J (2014) 0.95
Coagulation assessment with the new generation of oral anticoagulants. Emerg Med J (2015) 0.93
Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012. Am Heart J (2014) 0.92
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis (2016) 0.91
Positive outcome after intentional overdose of dabigatran. J Med Toxicol (2013) 0.89
Management of acute stroke in patients taking novel oral anticoagulants. Int J Stroke (2014) 0.89
A new era of stroke prevention in atrial fibrillation: comparing a new generation of oral anticoagulants with warfarin. Int Arch Med (2013) 0.86
Practical management of patients on apixaban: a consensus guide. Thromb J (2013) 0.86
Anticoagulation drug therapy: a review. West J Emerg Med (2015) 0.86
Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs (2014) 0.86
A practice tool for the new oral anticoagulants. Can Pharm J (Ott) (2014) 0.85
Rivaroxaban and hemostasis in emergency care. Emerg Med Int (2014) 0.84
Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence. Adv Hematol (2015) 0.84
Intracerebral haemorrhage associated with antithrombotic treatment: translational insights from experimental studies. Lancet Neurol (2013) 0.83
Translational insights into traumatic brain injury occurring during dabigatran or warfarin anticoagulation. J Cereb Blood Flow Metab (2014) 0.83
Beyond warfarin: The advent of new oral anticoagulants. Indian J Radiol Imaging (2016) 0.82
Reversal of oral anticoagulation. Pharmacotherapy (2013) 0.82
Tutorial in oral antithrombotic therapy: biology and dental implications. Med Oral Patol Oral Cir Bucal (2013) 0.82
Perioperative management of coagulation in nontraumatic intracerebral hemorrhage. Anesthesiology (2013) 0.81
Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism. Thromb J (2014) 0.81
[New oral anticoagulants for prophylaxis of stroke : Results of an expert conference on practical use in geriatric patients]. Z Gerontol Geriatr (2016) 0.80
Use of 4-factor prothrombin complex concentrate in the treatment of a gastrointestinal hemorrhage complicated by dabigatran. Int J Emerg Med (2015) 0.80
Diagnosis and Management of Acute Intracerebral Hemorrhage. Emerg Med Clin North Am (2016) 0.80
Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants. Cardiol Ther (2013) 0.79
Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices. Thromb Res (2013) 0.78
Oral anticoagulants in the management of venous thromboembolism. Nat Rev Cardiol (2013) 0.78
Blocking bleeding: reversing anticoagulant therapy. Nat Med (2013) 0.77
Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants. Biomed Res Int (2014) 0.76
New agents to prevent strokes in nonvalvular atrial fibrillation. Methodist Debakey Cardiovasc J (2012) 0.75
The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor. Thromb J (2017) 0.75
Prophylaxis and treatment of venous thromboembolism in the critically ill. Int J Crit Illn Inj Sci (2013) 0.75
Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy. Curr Drug Targets (2016) 0.75
Advances in Oral Coagulants. EJIFCC (2013) 0.75
Hemostasis in Intracranial Hemorrhage. Front Neurol (2017) 0.75
Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation. Ther Clin Risk Manag (2014) 0.75
Prothrombin complex concentrate. Hosp Pharm (2013) 0.75
New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty. World J Orthop (2014) 0.75
Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay. Br J Anaesth (2016) 0.75
Upper gastrointestinal endoscopy in emergency setting for patients receiving oral anticoagulants - practice updates. J Med Life (2017) 0.75
Emergency reversal of dabigatran for emergency surgery. BMJ Case Rep (2015) 0.75
Current state of anticoagulants to treat deep venous thrombosis. Curr Cardiol Rep (2014) 0.75
Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran. Drug Des Devel Ther (2016) 0.75
An in vitro anticoagulant effect of Fenugreek (Trigonella foenum-graecum) in blood samples of normal Sudanese individuals. Sudan J Paediatr (2013) 0.75
[Prevention of venous thromboembolism in musculoskeletal surgery]. Wien Klin Wochenschr (2014) 0.75
The Reversal of Direct Oral Anticoagulants in Animal Models. Shock (2017) 0.75
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med (2015) 10.86
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (2005) 9.04
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood (2011) 6.50
Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.88
Systematic overview of warfarin and its drug and food interactions. Arch Intern Med (2005) 5.86
Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med (2010) 5.23
Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet (2011) 4.78
Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med (2011) 4.59
The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.74
Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med (2008) 3.68
Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A (2007) 3.58
Effect of escitalopram on mental stress-induced myocardial ischemia: results of the REMIT trial. JAMA (2013) 3.48
The vexing problem of guidelines and conflict of interest: a potential solution. Ann Intern Med (2010) 3.47
Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med (2013) 3.40
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med (2012) 3.16
Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med (2006) 3.11
Acute kidney injury after cardiac surgery: focus on modifiable risk factors. Circulation (2009) 3.10
Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med (2012) 3.04
Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med (2015) 3.03
Using dabigatran in patients with stroke: a practical guide for clinicians. Stroke (2011) 2.97
Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost (2011) 2.75
RNA aptamers as reversible antagonists of coagulation factor IXa. Nature (2002) 2.73
Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer (2008) 2.72
A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med (2013) 2.68
D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med (2015) 2.63
An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost (2012) 2.54
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation (2003) 2.52
Indications, complications, and management of inferior vena cava filters: the experience in 952 patients at an academic hospital with a level I trauma center. JAMA Intern Med (2013) 2.52
Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med (2007) 2.50
Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 2.50
Antiphospholipid syndrome. Lancet (2010) 2.47
Venous thromboembolism: a public health concern. Am J Prev Med (2010) 2.37
Predicting deep venous thrombosis in pregnancy: out in "LEFt" field? Ann Intern Med (2009) 2.26
Comparison of characteristics from White- and Black-Americans with venous thromboembolism: a cross-sectional study. Am J Hematol (2010) 2.26
Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest (2013) 2.24
Advancing the study of stroke in women: summary and recommendations for future research from an NINDS-Sponsored Multidisciplinary Working Group. Stroke (2006) 2.17
Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation (2012) 2.16
Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. Ann Intern Med (2013) 2.15
A cautionary tale: fatal outcome of methotrexate therapy given for management of ectopic pregnancy. Obstet Gynecol (2006) 2.09
Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med (2005) 1.87
Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood (2009) 1.84
Liver disease in pregnancy. Lancet (2010) 1.84
Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J (2010) 1.82
Fresh frozen plasma transfusion in critically ill patients. Crit Care Med (2007) 1.81
Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med (2011) 1.78
Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med (2009) 1.77
Enoxaparin for neonatal thrombosis: a call for a higher dose for neonates. Thromb Res (2008) 1.72
Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ (2008) 1.71
American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol (2003) 1.67
Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood (2004) 1.67
Performance evaluation of the CellaVision DM96 system: WBC differentials by automated digital image analysis supported by an artificial neural network. Am J Clin Pathol (2005) 1.67
Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost (2008) 1.61
Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. J Am Coll Cardiol (2013) 1.61
Clinical use of a rapid collagen binding assay for von Willebrand factor cleaving protease in patients with thrombotic thrombocytopenic purpura. Thromb Haemost (2002) 1.57
A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Am J Gastroenterol (2007) 1.56
Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood (2010) 1.55
Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med (2002) 1.55
Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg (2007) 1.54
A red blood cell agglutination D-dimer test to exclude deep venous thrombosis in pregnancy. Ann Intern Med (2007) 1.53
Prophylaxis of Thromboembolism in Critical Care (PROTECT) Trial: a pilot study. J Crit Care (2005) 1.50
Varied opinions on thrombolysis for venous thromboembolism in infants and children: findings from a survey of pediatric hematology-oncology specialists. Pediatr Blood Cancer (2009) 1.50
Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg (2009) 1.49
Laboratory monitoring of new anticoagulants. Am J Hematol (2010) 1.49
Non-OO blood type influences the risk of recurrent venous thromboembolism. A cohort study. Thromb Haemost (2013) 1.47
Evaluation of a screening tool for bleeding disorders in a US multisite cohort of women with menorrhagia. Am J Obstet Gynecol (2011) 1.47
Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. Anesthesiology (2014) 1.47
A comparison of glass and plastic blood collection tubes for routine and specialized coagulation assays: a comprehensive study. Arch Pathol Lab Med (2006) 1.46
Cardiology patient pages. Homocysteine and MTHFR mutations: relation to thrombosis and coronary artery disease. Circulation (2005) 1.45
Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol (2009) 1.45
Warfarin-induced skin necrosis. J Am Acad Dermatol (2009) 1.44
Epstein-Barr virus reactivation and hemophagocytic lymphohistiocytosis in a patient with chronic lymphocytic leukemia. Leuk Lymphoma (2014) 1.44
Fetal-maternal hemorrhage detection in Ontario. Am J Clin Pathol (2003) 1.42
Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest (2005) 1.41
Postpartum management of women at increased risk of thrombosis--results of a Canadian pilot survey. J Rheumatol (2006) 1.40
Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization. Am J Clin Pathol (2012) 1.39
Randomized trial of physician alerts for thromboprophylaxis after discharge. Am J Med (2013) 1.39
Effect of marathon running on hematologic and biochemical laboratory parameters, including cardiac markers. Am J Clin Pathol (2002) 1.38
Blockade of tissue factor: treatment for organ injury in established sepsis. Am J Respir Crit Care Med (2003) 1.38
Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit (2010) 1.36
Prevalence and clinical characteristics of mental stress-induced myocardial ischemia in patients with coronary heart disease. J Am Coll Cardiol (2013) 1.34